Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance
- Registration Number
- NCT01240252
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The study is being conducted to find out why too much fat in your blood stream may cause insulin resistance in your muscles. Insulin is the hormone, produced normally by your body, which causes your blood sugar to return to normal after you eat.
- Detailed Description
Insulin resistance in skeletal muscle is an early event in the pathogenesis of type 2 diabetes, obesity, and other conditions associated with the Metabolic Syndrome. The aim of this study is to determine the extent to which the inflammatory response to lipids is present in naturally occurring insulin resistance. We will test the hypothesis that skeletal muscle from insulin resistant volunteers is characterized by:
1. Increased concentrations of circulating proinflammatory cytokines without changes in cytokine expression in muscle.
2. Increased inflammatory response in muscle.
3. Increased infiltration of inflammatory cells into skeletal muscle.
4. Changes in expression of proteasome genes.
Forty five subjects will be studied in total. Three groups will be studied. One group will consist of 15 patients with type 2 diabetes mellitus The second group will consist of 15 age, gender, and body composition matched overweight or obese subjects (27 \< BMI \<36) with normal glucose tolerance. The third group will consist of 15 age and gender matched nonobese control subjects (BMI \< 27).
There will be two visits in the study, a screening visit and the study visit. At visit 2 the subject will report to the study site having fasted since the night before, discuss the study and provide written consent, and provide a history and physical exam. Screening tests include a 12-lead resting EKG, complete blood chemistry and complete blood count (CBC), glycated hemoglobin (HbA1c), and a lipid profile. If the results of these tests show that the subject is eligible to participate in the study, a second visit will be scheduled. On the same day as the screening visit, the patient will have an oral glucose tolerance test.
Within 3 months of the screening visit, the subject will return after an overnight fast for a euglycemic clamp study and 2 muscle biopsies. Diabetic subjects will have oral medications discontinued for 3 days before study (metformin and thiazolidinedione treatment will be excluded). Patients taking insulin will have neutral protamine Hagedorn (NPH) discontinued the evening before study, and Glargine will be discontinued the morning and evening on the day before study. An antecubital catheter will be placed for infusion of substances. Deuterated glucose will be used to determine the rates of basal and insulin stimulated glucose uptake. A hand vein will be catheterized and placed in a heated box to arterialize venous blood for measurement of arterial glucose concentrations. One hour later, a percutaneous biopsy of the vastus lateralis muscle will be performed. Biopsy specimens (75-150 mg) will be frozen immediately in liquid nitrogen and stored in liquid nitrogen until they are processed. One hour after the muscle biopsy (two hours after the start of deuterated glucose), a primed-continuous (80 milliunits (mU)/(m\^2 per min)) insulin infusion will be started and continued for 120 minutes to quantify the effects of insulin on glucose disposal. Throughout the insulin infusion, an infusion of 20% glucose will be adjusted to maintain euglycemia. Plasma glucose in the diabetics will be allowed to fall during the insulin infusion to euglycemia, where it will be maintained. A second muscle biopsy will be performed in the contralateral leg at the conclusion of the insulin infusion.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Type 2 Diabetes Mellitus Subjects Human insulin Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours. Overweight or Obese Subjects with Normal Glucose Tolerance Human insulin Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours. Non-Obese Control Subjects Human insulin Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours.
- Primary Outcome Measures
Name Time Method Proportion of insulin resistant patients with elevated serine/threonine phosphorylation of IRS-1 in muscle. one month from date of volunteer study IRS-1 will be immunoprecipitated from percutaneous muscle biopsies, resolved by gel electrophoresis, digested with trypsin, and analyzed by high-performance liquid chromatography nanospray tandem mass spectrometry (MS/MS) analysis
- Secondary Outcome Measures
Name Time Method Quantitative assay of the ability of insulin to clear glucose from the blood in insulin resistant patients. one month from date if volunteer study The glucose clamp gives a quantitative measure, in mass per unit body weight per minute, of the ability of insulin to cause glucose to disappear from the blood
Trial Locations
- Locations (1)
Mayo Clinic in Arizona
🇺🇸Scottsdale, Arizona, United States